本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 成都圣诺生物科技股份有限公司（以下简称"公司"）第四届监事会第九次 会议通知于 2023 年 8 月 8 日以电话及邮件方式向各位监事发出，并于 2023 年 8 月 17 日在公司会议室以现场方式召开。会议由监事会主席曾德志先生召集和主 持。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集和召开程序 符合有关法律、法规、规范性文件和《成都圣诺生物科技股份有限公司章程》（以 下简称"《公司章程》"）的有关规定。 证券代码：688117 证券简称：圣诺生物 公告编号：2023-050 成都圣诺生物科技股份有限公司 第四届监事会第九次会议决议公告 二、监事会会议审议情况 经与会监事审议，做出如下决议： （一）审议通过《关于<公司 2023 年半年度报告及其摘要>的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 成都圣诺生物科技股份有限公司 监事会 2023 年 8 月 18 日 （二）审议通过《关于<公司 2023 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2023-051 成都圣诺生物科技股份有限公司 具体情况如下： 单位：人民币万元 关于2023年半年度募集资金存放与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》（证监会公告〔2022〕15 号）、《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》及相关格式指引的要求，成都圣诺 生物科技股份有限公司（以下简称"公司"或"圣诺生物"）董事会就 2023 年 半年度募集资金存放与实际使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 经中国证券监督管理委员会《关于同意成都圣诺生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕1497 号）同意注册，公司获准 向社会公众公开发行人民币普通股（A 股）20,000,000 股，每股面值人民币 1 元，每股发行价为人民币 17.90 元， ...

成都圣诺生物科技股份有限公司独立董事 关于第四届董事会第九次会议相关事项的独立意见 根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》等 法规以及《成都圣诺生物科技股份有限公司章程》《成都圣诺生物科技股份有限 公司独立董事制度》等公司制度的规定，我们作为成都圣诺生物科技股份有限公 司（以下简称"公司"）的独立董事，本着对公司及全体股东负责的态度，基于 审慎独立判断的立场，认真审阅了公司第四届董事会第九次会议的相关议案，现 发表独立意见如下： 一、《关于<公司 2023 年半年度募集资金存放与实际使用情况的专项报告> 的议案》的独立意见 经核查，我们认为公司 2023 年半年度募集资金的存放和使用符合《上海证 券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》等相关法律、法规及其他规范性文件和公司《募集资金管 理制度》的相关规定，募集资金通过专户存储和专项使用，公司所披露信息真实、 准确、完整，与募集资金的实际使用情况一致，不存在改变或变相改变募集资金 用途和损害股东利益的情形，不存在违规存放和使用募集资金的情形，因此，我 们一致同意本议案。 （本页以 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2023-048 成都圣诺生物科技股份有限公司 关于持股 5%以上股东减持股份计划公告 公司于近日收到股东乐普医疗出具的《关于股东减持计划的告知函》,因股 东自身资金需求，乐普医疗拟通过集中竞价、大宗交易的方式减持其持有的公司 股份合计不超过 2,912,000 股，即不超过公司总股本的 2.60%。拟通过集中竞价 方式减持的部分，自本公告披露之日起 15 个交易日之后的 3 个月内进行, 且任 意连续 90 个自然日内减持的股份总数不超过公司股份总数的 1%；拟通过大宗交 易方式减持的部分，自本公告披露之日起 3 个交易日之后的 3 个月内进行, 且任 意连续 90 个自然日内减持的股份总数不超过公司股份总数的 2%。 如遇派息、送股、转增股本、配股等除权除息事项，上述拟减持股份数量将 相应进行调整，但减持股份占公司总股本的比例不变。 现将具体情况公告如下： 一、减持主体的基本情况 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股 ...

证券代码：688117 证券简称：圣诺生物 公告编号:2023-049 成都圣诺生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 24 日(星期四) 上午 10:00-11:00 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 8 月 17 日(星期四)至 2023 年 8 月 23 日(星期三)下午 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 (snkj@snbiopharm.com)进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 成都圣诺生物科技股份有限公司（以下简称"公司"）将于 2023 年 8 月 18 日在上海证券交易所网站（www.sse.com.cn）披露公司《2023 年半年度报告》， 为便于广大投资 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2023-047 成都圣诺生物科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 成都圣诺生物科技股份有限公司（以下简称"公司"）股票于 2023 年 8 月 9 日、8 月 10 日和 8 月 11 日连续三个交易日内收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易 实时监控细则》（以下简称"《实时监控细则》"）的有关规定，属于股票交易 异常波动情形。 经公司自查，公司目前日常经营情况正常，未发生重大变化。经公司向 控股股东、实际控制人书面询证，截至本公告披露日，公司不存在应披露而未披 露的重大信息。 公司关注到，近期市场面对糖尿病和减重治疗药物利拉鲁肽、司美格鲁 肽有所关注。而公司利拉鲁肽及利拉鲁肽注射液仿制药项目在国内尚处于临床 I 期阶段、司美格鲁肽现处于临床前研究阶段，均处于研发投入期；公司利拉鲁原 料药 2015 年 10 月在美国 DMF 备案，目前尚无 ...

《关于成都圣诺生物科技股份有限公司股票交易异常波动 的询证函》的回函 致：成都圣诺生物科技股份有限公司 贵公司《关于成都圣诺生物科技股份有限公司股票交易异常波动的询证函》 已收悉，经本人认真自查核实，现就公司询证事项回复如下： 截至目前，作为贵公司实际控制人，本人不存在涉及贵公司应披露而未披露 的重大信息，不存在正在筹划重大资产重组、发行股份、上市公司收购、债务重 组、业务重组、资产剥离和资产注入等重大事项。 本人及一致行动人在公司股票异常波动期间，不存在买卖公司股票的行为。 特此回函。 （本页以下无正文） （本页无正文，为实际控制人《<关于成都圣诺生物科技股份有限公司股票 交易异常波动的询证函>的回函》之签署页。） 实际控制人: 2025年8月11日 《关于成都圣诺生物科技股份有限公司股票交易异常波动 的询证函》的回函 致：成都圣诺生物科技股份有限公司 贵公司《关于成都圣诺生物科技股份有限公司股票交易异常波动的询证函》 已收悉，经本人认真自查核实，现就公司询证事项回复如下： 截至目前，作为贵公司实际控制人，本人不存在涉及贵公司应披露而未披露 的重大信息，不存在正在筹划重大资产重组、发行股份、上市公司收购、债 ...

Financial Performance - The company reported a significant increase in revenue, reaching RMB 1.5 billion, representing a 20% year-over-year growth[17]. - The company's operating revenue for 2022 was CNY 395.72 million, an increase of 2.38% compared to CNY 386.53 million in 2021[23]. - The net profit attributable to shareholders for 2022 was CNY 64.48 million, reflecting a growth of 5.28% from CNY 61.25 million in 2021[23]. - The net cash flow from operating activities increased by 82.44% to CNY 95.62 million, primarily due to an increase in received payments and a reduction in market business expenses[25]. - The basic earnings per share for 2022 was CNY 0.81, down 4.71% from CNY 0.85 in 2021[25]. - The company reported a decrease in the net profit after deducting non-recurring gains and losses, which was CNY 56.60 million, down 2.59% from CNY 58.10 million in 2021[23]. - The company achieved a net profit of 6,596.58 CNY million from its main business operations in the reporting period[148]. Dividend and Capital Increase - The company plans to distribute a cash dividend of 2.50 CNY per 10 shares, totaling approximately 20 million CNY, which represents 31.02% of the net profit attributable to shareholders for 2022[6]. - The company will increase its share capital by 4 shares for every 10 shares held, resulting in a total increase of 32 million shares, changing the total share capital to 112 million shares[6]. - The board of directors has approved the profit distribution and capital increase plan, pending approval from the annual general meeting[7]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5]. - The company has confirmed that there are no violations of decision-making procedures for external guarantees[10]. - The company has stated that all board members can guarantee the authenticity, accuracy, and completeness of the annual report[10]. - The company has not reported any major discrepancies in governance compared to regulatory requirements[169]. - The company has not faced any penalties from securities regulatory authorities in the past three years, indicating compliance with regulations[189]. Research and Development - The company is investing in R&D, with a budget increase of 30% to enhance innovation capabilities[17]. - The company's R&D expenditure as a percentage of operating revenue rose to 6.50%, an increase of 1.76 percentage points from 4.74% in 2021[25]. - R&D expenses increased by 40.29% year-over-year, totaling ¥25,714,181.48, primarily due to the one-time evaluation of Loxisomab injection[73]. - The company has several ongoing projects, including Liraglutide, which has a total investment of ¥5,000 million and is currently in clinical trials[75]. - The company has developed 16 self-researched peptide raw materials, with 11 products receiving production licenses or activation records in the domestic market[47]. - The company is focusing on expanding its core technology team, with several key personnel holding significant positions[178]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[17]. - Market expansion plans include entering two new international markets by Q3 2023[17]. - The company is exploring potential acquisitions to strengthen its product portfolio, targeting a deal valued at approximately RMB 500 million[17]. - The company aims to improve operational efficiency, targeting a 15% reduction in production costs by the end of 2023[17]. - The company plans to enhance its competitive position in the peptide CDMO service sector and expand its product line in high-value peptide raw materials[129]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company faces risks related to the consistency evaluation of generic drugs, which could impact its competitive advantage if not completed within the required timeframe[90]. - The company is exposed to macroeconomic risks that could adversely affect its operating conditions and profitability due to global economic downturns[95]. Human Resources and Governance - The company has established a comprehensive human resources management system to enhance the capabilities of its technical and management teams[42]. - The total number of employees in the parent company and major subsidiaries is 879, with 411 in production, 304 in technical roles, and 127 in administration[200]. - The company maintained a transparent and effective performance evaluation and incentive mechanism, linking employee income to industry and company performance[168]. Product Development and Pipeline - The company has provided over 40 pharmaceutical research services for new drug development, with 1 product approved for commercialization and 18 innovative peptides entering clinical trials[37]. - The company is actively pursuing new product approvals, with several drugs already submitted for regulatory review, including a treatment for hereditary angioedema[76]. - The company has several products in various stages of development, including Liraglutide and Ecallantide, with some products currently under review and others having completed clinical trials[134]. Financial Management - The company’s financing activities generated a net cash flow of RMB 42.25 million, a decrease of 86.47% compared to RMB 312.20 million in the previous year[97]. - Cash and cash equivalents at the end of the period amounted to 372,122,126.73 yuan, representing 33.58% of total assets, an increase of 75.89% from the previous period[117]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 6.4452 million RMB[187]. Strategic Initiatives - The company plans to focus on high-demand therapeutic areas such as oncology, diabetes, and gastrointestinal diseases, enhancing its R&D capabilities to maintain competitive advantages[156]. - The company intends to leverage its capital platform to explore potential investment opportunities and enhance its market competitiveness[158]. - The company is committed to increasing its R&D investment to develop high-tech, safe, and stable peptide drugs[152].

Financial Performance - The company's operating revenue for Q1 2023 was ¥81,516,580.85, representing a year-on-year increase of 0.96%[5]. - The net profit attributable to shareholders decreased by 1.82% to ¥14,032,925.44, while the net profit after deducting non-recurring gains and losses dropped significantly by 48.25% to ¥6,278,006.01[5][8]. - Total revenue for Q1 2023 was CNY 81,516,580.85, a slight increase of 1.0% compared to CNY 80,744,800.39 in Q4 2022[19]. - Net profit for Q1 2023 was CNY 14,032,925.44, a decrease of 1.8% from CNY 14,292,867.60 in Q4 2022[19]. - The net profit attributable to the parent company for Q1 2023 is CNY 14,032,925.44, compared to CNY 14,292,867.60 in Q1 2022, indicating a slight decrease[20]. - The total comprehensive income attributable to the parent company for Q1 2023 is CNY 14,032,925.44, down from CNY 14,292,867.60 in the same period last year[20]. - The basic and diluted earnings per share for Q1 2023 remain at CNY 0.18, unchanged from Q1 2022[20]. Cash Flow - The net cash flow from operating activities fell by 41.72% to ¥17,230,314.83, attributed to reduced sales collections and increased employee compensation payments[5][8]. - Cash inflows from operating activities for Q1 2023 amount to CNY 229,885,043.78, an increase from CNY 156,155,336.62 in Q1 2022[22]. - The net cash flow from operating activities for Q1 2023 is CNY 17,230,314.83, down from CNY 29,565,224.06 in Q1 2022[22]. - The net cash flow from investing activities for Q1 2023 is -CNY 175,165,401.28, compared to a positive CNY 19,110,356.37 in Q1 2022[23]. - Cash inflows from financing activities for Q1 2023 total CNY 140,000,000.00, significantly higher than CNY 10,000,000.00 in Q1 2022[23]. - The net cash flow from financing activities for Q1 2023 is CNY 127,206,627.92, compared to CNY 9,391,908.39 in Q1 2022[23]. - The ending cash and cash equivalents balance for Q1 2023 is CNY 340,592,596.07, up from CNY 268,158,720.07 at the end of Q1 2022[23]. - The company received CNY 1,439,471.11 in tax refunds during Q1 2023, compared to CNY 77,628.60 in Q1 2022[22]. Assets and Liabilities - The total assets at the end of the reporting period increased by 13.38% to ¥1,256,249,613.62 compared to the end of the previous year[6]. - Total assets increased to CNY 1,256,249,613.62, up from CNY 1,108,008,638.28, reflecting a growth of 13.4%[16]. - Total liabilities rose to CNY 415,445,853.87, an increase of 47.7% compared to CNY 281,271,366.55 in Q4 2022[16]. - The company’s total equity increased to CNY 840,803,759.75 from CNY 826,737,271.73, reflecting a growth of 1.7%[16]. - Long-term borrowings increased significantly to CNY 179,186,416.42 from CNY 48,052,800.00, indicating a strategic shift in financing[16]. Research and Development - The company's R&D investment totaled ¥6,158,199.18, accounting for 7.55% of operating revenue, a slight decrease of 0.01 percentage points[6]. - Research and development expenses for Q1 2023 were CNY 4,862,883.56, slightly down from CNY 5,112,082.43 in Q4 2022[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,815[10]. - Chengdu Sainuo Investment Co., Ltd. held 37.50% of the shares, making it the largest shareholder[10]. Other Information - The company did not disclose any new product developments or market expansion strategies during the reporting period[12]. - The company reported non-recurring gains of ¥7,754,919.43, primarily from government subsidies and other income[7]. - Cash and cash equivalents decreased to CNY 340,592,596.07 from CNY 372,122,126.73, representing a decline of 8.5%[14]. - The company reported a significant increase in inventory, which rose to CNY 159,832,819.20 from CNY 135,434,477.07, marking an increase of 18.0%[14].

证券代码：688117 证券简称：圣诺生物 公告编号：2023-013 成都圣诺生物科技股份有限公司 关于召开 2022 年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址 http://roadshow.sseinfo.com/） 本次投资者说明会以网络文字互动形式召开，公司将针对 2022 年年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开时间、地点 （一）会议召开时间：2023 年 5 月 4 日（星期四）上午 10:00-11:00 会议召开方式：上证路演中心网络文字互动 投资者可以于 2023 年 4 月 24 日(星期一)至 2023 年 4 月 28 日(星期五) 下午 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱（snkj@snbiopharm.com）进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 成都圣诺生物科技股份有限公司（以 ...